{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T04:46:13Z","timestamp":1783745173750,"version":"3.55.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,5,30]],"date-time":"2016-05-30T00:00:00Z","timestamp":1464566400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s10557-016-6666-1","type":"journal-article","created":{"date-parts":[[2016,5,29]],"date-time":"2016-05-29T23:43:31Z","timestamp":1464565411000},"page":"305-313","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia"],"prefix":"10.1007","volume":"30","author":[{"given":"Robert S.","family":"Rosenson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry A.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Preiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Stephen","family":"Djedjos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Dent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Bridges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,5,30]]},"reference":[{"key":"6666_CR1","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1194\/jlr.R026658","volume":"53","author":"G Lambert","year":"2012","unstructured":"Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK. The PCSK9 decade. J Lipid Res. 2012;53:2515\u201324.","journal-title":"J Lipid Res"},{"key":"6666_CR2","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s11883-013-0310-3","volume":"15","author":"EA Stein","year":"2013","unstructured":"Stein EA, Swergold GD. Potential of proprotein convertase subtilisin\/kexin type 9 based therapeutics. Curr Atheroscler Rep. 2013;15:310.","journal-title":"Curr Atheroscler Rep"},{"key":"6666_CR3","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","volume":"370","author":"DJ Blom","year":"2014","unstructured":"Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370:1809\u201319.","journal-title":"N Engl J Med"},{"key":"6666_CR4","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","volume":"380","author":"RP Giugliano","year":"2012","unstructured":"Giugliano RP, Desai NR, Kohli P, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet. 2012;380:2007\u201317.","journal-title":"Lancet"},{"key":"6666_CR5","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","volume":"63","author":"MJ Koren","year":"2014","unstructured":"Koren MJ, Lundqvist P, Bolognese M, et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol. 2014;63:2531\u201340.","journal-title":"J Am Coll Cardiol"},{"key":"6666_CR6","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1161\/CIRCULATIONAHA.113.007012","volume":"129","author":"MJ Koren","year":"2014","unstructured":"Koren MJ, Giugliano RP, Raal FJ, et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. Circulation. 2014;129:234\u201343.","journal-title":"Circulation"},{"key":"6666_CR7","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(12)61771-1","volume":"380","author":"MJ Koren","year":"2012","unstructured":"Koren MJ, Scott R, Kim JB, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2012;380:1995\u20132006.","journal-title":"Lancet"},{"key":"6666_CR8","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"F Raal","year":"2012","unstructured":"Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 2012;126:2408\u201317.","journal-title":"Circulation"},{"key":"6666_CR9","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","volume":"63","author":"E Stroes","year":"2014","unstructured":"Stroes E, Colquhoun D, Sullivan D, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol. 2014;63:2541\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"6666_CR10","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","volume":"308","author":"D Sullivan","year":"2012","unstructured":"Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA. 2012;308:2497\u2013506.","journal-title":"JAMA"},{"key":"6666_CR11","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","volume":"385","author":"FJ Raal","year":"2015","unstructured":"Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;385:331\u201340.","journal-title":"Lancet"},{"key":"6666_CR12","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.2014.4030","volume":"311","author":"JG Robinson","year":"2014","unstructured":"Robinson JG, Nedergaard BS, Rogers WJ, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014;311:1870\u201382.","journal-title":"JAMA"},{"key":"6666_CR13","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1161\/CIRCULATIONAHA.113.001969","volume":"128","author":"NR Desai","year":"2013","unstructured":"Desai NR, Kohli P, Giugliano RP, et al. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial. Circulation. 2013;128:962\u20139.","journal-title":"Circulation"},{"key":"6666_CR14","first-page":"3134","volume":"86","author":"TC Ooi","year":"2001","unstructured":"Ooi TC, Cousins M, Ooi DS, et al. Postprandial remnant-like lipoproteins in hypertriglyceridemia. J Clin Endocrinol Metab. 2001;86:3134\u201342.","journal-title":"J Clin Endocrinol Metab"},{"key":"6666_CR15","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.bbalip.2011.11.010","volume":"1821","author":"HC Hassing","year":"2012","unstructured":"Hassing HC, Surendran RP, Mooij HL, Stroes ES, Nieuwdorp M, Dallinga-Thie GM. Pathophysiology of hypertriglyceridemia. Biochim Biophys Acta. 2012;1821:826\u201332.","journal-title":"Biochim Biophys Acta"},{"key":"6666_CR16","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","volume":"372","author":"MS Sabatine","year":"2015","unstructured":"Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500\u20139.","journal-title":"N Engl J Med"},{"key":"6666_CR17","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","volume":"129","author":"NJ Stone","year":"2014","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1\u201345.","journal-title":"Circulation"},{"key":"6666_CR18","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","volume":"123","author":"M Miller","year":"2011","unstructured":"Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123:2292\u2013333.","journal-title":"Circulation"},{"key":"6666_CR19","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1016\/j.jacc.2014.09.042","volume":"64","author":"RS Rosenson","year":"2014","unstructured":"Rosenson RS, Davidson MH, Hirsh BJ, Kathiresan S, Gaudet D. Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease. J Am Coll Cardiol. 2014;64:2525\u201340.","journal-title":"J Am Coll Cardiol"},{"key":"6666_CR20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jacl.2015.02.003","volume":"9","author":"TA Jacobson","year":"2015","unstructured":"Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1\u2013full report. J Clin Lipidol. 2015;9:129\u201369.","journal-title":"J Clin Lipidol"},{"key":"6666_CR21","doi-asserted-by":"crossref","first-page":"587","DOI":"10.5812\/ijem.4783","volume":"10","author":"CE Samson","year":"2012","unstructured":"Samson CE, Galia AL, Llave KI, Zacarias MB, Mercado-Asis LB. Postprandial peaking and plateauing of triglycerides and VLDL in patients with underlying cardiovascular diseases despite treatment. Int J Endocrinol Metab. 2012;10:587\u201393.","journal-title":"Int J Endocrinol Metab"},{"key":"6666_CR22","doi-asserted-by":"crossref","unstructured":"National Cholesterol Education Program Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143\u2013421.","DOI":"10.1161\/circ.106.25.3143"},{"key":"6666_CR23","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","volume":"366","author":"C Baigent","year":"2005","unstructured":"Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267\u201378.","journal-title":"Lancet"},{"key":"6666_CR24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11892-009-0004-y","volume":"9","author":"H Neeli","year":"2009","unstructured":"Neeli H, Gadi R, Rader DJ. Managing diabetic dyslipidemia: beyond statin therapy. Curr Diab Rep. 2009;9:11\u20137.","journal-title":"Curr Diab Rep"},{"key":"6666_CR25","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000759","volume":"3","author":"G Thanassoulis","year":"2014","unstructured":"Thanassoulis G, Williams K, Ye K, et al. Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trials. J Am Heart Assoc. 2014;3:e000759.","journal-title":"J Am Heart Assoc"},{"key":"6666_CR26","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1001\/jama.2012.366","volume":"307","author":"SM Boekholdt","year":"2012","unstructured":"Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012;307:1302\u20139.","journal-title":"JAMA"},{"key":"6666_CR27","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1161\/CIRCULATIONAHA.113.002670","volume":"128","author":"SM Boekholdt","year":"2013","unstructured":"Boekholdt SM, Arsenault BJ, Hovingh GK, et al. Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis. Circulation. 2013;128:1504\u201312.","journal-title":"Circulation"},{"key":"6666_CR28","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1258\/acb.2011.010277","volume":"48","author":"H Soran","year":"2011","unstructured":"Soran H, France MW, Kwok S, et al. Apolipoprotein B100 is a better treatment target than calculated LDL and non-HDL cholesterol in statin-treated patients. Ann Clin Biochem. 2011;48:566\u201371.","journal-title":"Ann Clin Biochem"},{"key":"6666_CR29","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1161\/01.ATV.0000022015.97341.3A","volume":"22","author":"L Kuller","year":"2002","unstructured":"Kuller L, Arnold A, Tracy R, et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol. 2002;22:1175\u201380.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"6666_CR30","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1210\/jc.2003-030636","volume":"88","author":"FM Sacks","year":"2003","unstructured":"Sacks FM, Campos H. Clinical review 163: cardiovascular endocrinology: low-density lipoprotein size and cardiovascular disease: a reappraisal. J Clin Endocrinol Metab. 2003;88:4525\u201332.","journal-title":"J Clin Endocrinol Metab"},{"key":"6666_CR31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1161\/01.CIR.95.1.69","volume":"95","author":"B Lamarche","year":"1997","unstructured":"Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation. 1997;95:69\u201375.","journal-title":"Circulation"},{"key":"6666_CR32","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.jacc.2008.02.034","volume":"51","author":"JD Brunzell","year":"2008","unstructured":"Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2008;51:1512\u201324.","journal-title":"J Am Coll Cardiol"},{"key":"6666_CR33","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1373\/clinchem.2008.111401","volume":"55","author":"V Charlton-Menys","year":"2009","unstructured":"Charlton-Menys V, Betteridge DJ, Colhoun H, et al. Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). Clin Chem. 2009;55:473\u201380.","journal-title":"Clin Chem"}],"updated-by":[{"DOI":"10.1007\/s10557-016-6684-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2016,8,6]],"date-time":"2016-08-06T00:00:00Z","timestamp":1470441600000}}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-016-6666-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-016-6666-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-016-6666-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,8]],"date-time":"2019-09-08T21:09:55Z","timestamp":1567976995000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-016-6666-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,30]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["6666"],"URL":"https:\/\/doi.org\/10.1007\/s10557-016-6666-1","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10557-016-6684-z","asserted-by":"object"}]},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,30]]}}}